RPL7L1P10

Across TCGA pan-cancer cohorts, RPL7L1P10 RNA is linked to patient survival in 5 of 34 cancer types, making it the most broadly survival-associated RPL7L1P10 data layer.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher RPL7L1P10 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RPL7L1P10 expression acts as an unfavorable survival marker.

BLCA, LAML, and SKCM are the cancer types where RPL7L1P10 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Tertile	All	0.142	0.618	<.001	108	view →
LAML	DFS	Tertile	All	0.185	0.588	<.001	54	view →
SKCM	DFS	Tertile	All	0.158	0.761	<.001	45	view →
KIRC	DFS	Tertile	IV	0.127	0.619	.008	36	view →
HNSC	DFS	Tertile	II,III,IV	0.163	0.695	.013	27	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RPL7L1P10–BLCA (DFS)

Open the BLCA breakdown →